Cashmaker's hot stocks and trading

HLTH buy back 20% (60 Million shares) of its outstanding shares, very good sign to its stock price. Like Peter Lynch said in his book: there are many reasons that the insiders sell their shares, but there is only one reason they buy: the stock is undervalued and is cheap. We will see HLTH easily to $10

Finance; Emdeon announces commencement of its tender offer

2005 DEC 25 - (NewsRx.com) -- Emdeon Corp. (HLTH) announced that it has commenced its tender offer to purchase up to 60,000,000 shares of its common stock at a price per share of $8.20.

The number of shares proposed to be purchased in the tender offer represents approximately 17.4% of the company's currently outstanding shares. The last reported sales price per share of the company's common stock on the Nasdaq national market on November 22, 2005, was $7.75 per share.

The company's directors and executive officers have advised the company they do not intend to tender any of their shares in the tender offer.

The tender offer is scheduled to expire December 21, 2005, unless extended by the company. Tenders of shares must be made on or prior to the expiration of the tender offer and may be withdrawn at any time on or prior to the expiration of the tender offer.

The tender offer is subject to a number of terms and conditions described in the offer to purchase that is being distributed to stockholders, including that a minimum of 27,500,000 shares be properly tendered and not properly withdrawn in the offer.

On the terms and subject to the conditions of the tender offer, the company's stockholders will have the opportunity to tender some or all of their shares at a price of $8.20 per share. If stockholders properly tender and do not properly withdraw more than 60,000,000 shares, the company will purchase shares tendered by those stockholders owning fewer than 100 shares, without pro ration, and all other shares tendered will be purchased on a pro rata basis, subject to the conditional tender offer provisions described in the offer to purchase that is being distributed to stockholders.

Stockholders whose shares are purchased in the tender offer will be paid $8.20 per share, net in cash, without interest, promptly after the expiration of the tender offer period.
 
RNAI a strong buy here,Bio analysts recommend it last week with target $8-$10 in 2006. RNAI made a significant progress Hepatitis C antiviral program,and completed its preclinical evaluation of the efficacy of Sirna-AV34 and has begun cGMP manufacturing for its Phase I clinical studies. Analysts said if this drug pass the phase III, it will dominant the Hepatitis C drug market and it is a revolutionary progress on Hepatitis C therapy.

Following is the article last week on Morningstar, very positive report on RNAI Hepatitis C research.

Sirna Therapeutics Selects Development Candidate for Its Hepatitis C Antiviral Program


12-21-05 08:03 AM EST | Systemically Delivered siRNA Designed to Dramatically Reduce Drug Resistant Variants

/PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc. (Nasdaq: RNAI), a leading RNAi therapeutics company, announced today that it has selected Sirna-AV34, a systemically delivered, chemically modified short interfering RNA (siRNA) compound, as its candidate for advancement to human clinical testing against Hepatitis C virus. Sirna completed its preclinical evaluation of the efficacy of Sirna-AV34 and has begun cGMP manufacturing for its Phase I clinical studies. Sirna expects to initiate IND-enabling toxicology studies in the first quarter of 2006 followed by the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) by the fourth quarter of 2006.

Sirna-AV34 is a systemically delivered, nanoparticle-based therapeutic targeting the Hepatitis C virus. The compound consists of multiple individual, chemically modified, siRNA sequences which target highly conserved sequences in the Hepatitis C viral genome. Sirna-AV34 is designed to inhibit viral replication and dramatically reduce the selection of drug resistant mutant variants. The design principles used in Sirna-AV34 were validated by demonstrating reduction in escape mutation frequency in the Hepatitis C virus sub-genomic replicon system in vitro. No existing therapeutic approach has the potential to broadly inhibit Hepatitis C viral replication while reducing the probability of drug resistant variants.

"We are extremely pleased by the significant progress of our Hepatitis C antiviral program," stated Sirna Senior Vice President and Chief Scientific Officer, Barry Polisky, PhD. "The selection of Sirna-AV34 as our clinical candidate reflects two major accomplishments of our research team. The first is the design, chemical modification and synthesis of a stable and potent siRNA compound which is effective broadly against the Hepatitis C virus. The second is the development of a proprietary nanoparticle delivery technology capable of efficient and specific delivery of the siRNA compound to hepatocytes. These two achievements have provided us with a unique opportunity to bring this groundbreaking therapy to the clinic."

Sirna has completed its preclinical evaluation including demonstration of systemic efficacy in both rodent and non-human primate animal models. As previously reported in a rodent model of Hepatitis B virus used as a surrogate for Hepatitis C virus, Sirna demonstrated that a chemically optimized and encapsulated siRNA had significant antiviral activity and prolonged duration of effect in vivo. Recent data from a non-human primate model of Hepatitis C replication demonstrated that Sirna's systemically delivered siRNA compound dramatically suppressed Hepatitis C viral titers via an RNA interference mechanism.

"We are very excited to be moving a systemically delivered siRNA towards the clinic," stated Roberto Guerciolini, MD, Senior Vice President and Chief Medical Officer. "Since the current treatments for chronic Hepatitis C remain highly unsatisfactory, we believe that the application of an siRNA compound targeting multiple components of the viral genome will result in a significant advancement in the treatment of this disease."

Sirna-AV34 will be manufactured at Sirna's cGMP facilities in Boulder, Colorado for both Phase I enabling toxicology studies and Phase I human clinical testing.

About Sirna Therapeutics

Sirna Therapeutics is a clinical-stage biotechnology company developing RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis B and C, dermatology, asthma, Huntington's disease, diabetes and oncology. Sirna Therapeutics has presented interim Phase 1 clinical trial data for its most advanced compound, Sirna-027, a chemically optimized siRNA targeting the clinically validated vascular endothelial growth factor pathway to treat AMD. Sirna-027, which has been partnered with Allergan, Inc., has been shown to be safe and well tolerated with a trend toward visual acuity improvement and demonstrated biological activity. Sirna has a leading intellectual property portfolio in RNAi with 45 issued patents and over 250 pending applications worldwide. More information on Sirna Therapeutics is available on the Company's web site at http://www.sirna.com.

Safe Harbor Statement

Statements in this press release which are not strictly historical are "forward-looking" statements which should be considered as subject to many risks and uncertainties. For example, Sirna's ability to develop a treatment for Hepatitis C will require additional, much more costly clinical trials, the results of which are highly uncertain. Moreover, Sirna's ability to develop products and operate as a going concern requires significant cash to fund its operating programs. Additional risks and uncertainties include Sirna's early stage of development and short operating history, Sirna's history and expectation of losses and need to raise capital, Sirna's need to obtain clinical validation and regulatory approval for products, Sirna's need to obtain and protect intellectual property, risk of third-party patent infringement claims, Sirna's need to attract and retain qualified personnel, Sirna's need to engage collaborators, availability of materials for product manufacturing, the highly competitive nature of the pharmaceutical market, the limited trading volume and history of volatility of Sirna's common stock, Sirna's concentration of stock ownership, and risks from relocating Sirna headquarters. These and additional risk factors are identified in Sirna's Securities and Exchange Commission filings, including the Forms 10-K and 10-Q and in other SEC filings. Sirna undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
 
The RNAi Market is Predicted to Be Worth $850 Million by 2010 and is Expected to Further Increase to $1.2 Billion by 2015

DUBLIN, Ireland --(Business Wire)-- Dec. 15, 2005 -- Research and Markets (http://www.researchandmarkets.com/reports/c1589) has announced the addition of the Jain PharmaBiotech report: RNAi -- Technologies, Markets and Companies to their offering.



The markets for RNAi are difficult to define as no RNAi-based product is in clinical development yet. The major use of RNAi reagents is in research but it partially overlaps that of drug discovery and therapeutic development. It is estimated to be $400 million currently in 2005,$850 million by the year 2010 and $1.2 billion by the year 2015. The value of the drug discovery market based on RNAi can be assessed at $650 million in the year 2005, increasing to $1 billion in the year 2010 and $1.5 billion in 2015. Even if a few products get into the market by the year 2010, this market will expand to $3.5 billion based on revenues from sales of RNAi- based drugs and increase further to $5.9 billion in 2015. Markets are also analyzed according to breakdown of technologies and use of siRNAs, miRNAs, etc.

Profiles of 126 companies involved in developing RNAi technologies are presented along with 105 collaborations. They are a mix of companies that supply reagents and technologies (nearly half of all) and companies that use the technologies for drug discovery. Approximately 18 of these are developing RNAi-based therapeutics. The bibliography contains selected 300 publications that are cited in the report. The text is supplemented with 25 tables and 7 figures.

RNA interference (RNAi) or gene silencing involves the use of double stranded RNA (dsRNA). Once inside the cell, this material is processed into short 21-23 nucleotide RNAs termed siRNAs that are used in a sequence-specific manner to recognize and destroy complementary RNA. The report compares RNAi with other antisense approaches using oligonucleotides, aptamers, ribozymes, peptide nucleic acid and locked nucleic acid.

Various RNAi technologies are described, along with design and methods of manufacture of siRNA reagents. These include chemical synthesis by in vitro transcription and use of plasmid or viral vectors. Other approaches to RNAi include DNA-directed RNAi (ddRNAi) that is used to produce dsRNA inside the cell, which is cleaved into siRNA by the action of Dicer, a specific type of RNAse III. MicroRNAs are derived by processing of short hairpins that can inhibit the mRNAs. Expressed interfering RNA (eiRNA) is used to express dsRNA intracellularly from DNA plasmids.

Delivery of therapeutics to the target tissues is an important consideration. siRNAs can be delivered to cells in culture by electroporation or by transfection using plasmid or viral vectors. In vivo delivery of siRNAs can be carried out by injection into tissues or blood vessels or use of synthetic and viral vectors.

Because of its ability to silence any gene once the sequence is known, RNAi has been adopted as the research tool to discriminate gene function. After the genome of an organism is sequenced, RNAi can be designed to target every gene in the genome and target for specific phenotypes. Several methods of gene expression analysis are available and there is still need for sensitive methods of detection of gene expression as a baseline and measurement after gene silencing. RNAi microarray has been devised and can be tailored to meet the needs for high throughput screens for identifying appropriate RNAi probes. RNAi is an important method for analyzing gene function and identifying new drug targets that uses double-stranded RNA to knock down or silence specific genes. With the advent of vector-mediated siRNA delivery methods it is now possible to make transgenic animals that can silence gene expression stably. These technologies point to the usefulness of RNAi for drug discovery.

RNAi can be rationally designed to block the expression of any target gene, including genes for which traditional small molecule inhibitors cannot be found. Areas of therapeutic applications include virus infections, cancer, genetic disorders and neurological diseases. Side effects can result from unintended interaction between an siRNA compound and an unrelated host gene. If RNAi compounds are designed poorly, there is an increased chance for non-specific interaction with host genes that may cause adverse effects in the host.

Regulatory, safety and patent issues are discussed. There are no major safety concerns and regulations are in preliminary stages as the clinical trials are just starting. Many of the patents are still pending. -0- *T Topics Covered: Executive Summary 1 Technologies for suppressing gene function 2 RNAi Technologies 3 MicroRNA 4 Methods of delivery in RNAi 5 RNAi in Research 6 RNAi in drug discovery 7 Therapeutic applications of RNAi 8 Safety, regulatory and patent issues 9 Markets for RNAi Technologies 10 Companies involved in RNAi Technologies 11 References *T
 
Comment on RNAI's new technology and products. You might not know how big the RNAi market is and how well it can be used in treating hepatitis B and C, dermatology, asthma, Huntington disease, diabetes and oncology and AIDS and more. The RNAi Market is Predicted to Be Worth $850 Million by 2010 and is Expected to Further Increase to $1.2 Billion by 2015. When the time RNAi announce its new drug, those big firms, such as VRX, SGP have to use its license.

Sirna Therapeutics is a clinical-stage biotechnology company developing RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis B and C, dermatology, asthma, Huntington disease, diabetes and oncology.

Sirna Therapeutics has presented interim phase I clinical trial data for its most advanced compound Sirna-027, a chemically optimized siRNA targeting the clinically validated vascular endothelial growth factor pathway to treat AMD.

Recently, even government pay attention to RNAi tech.Alnylam Pharmaceuticals Inc.received initial government funding to develop RNA interference therapy for pandemic influenza. You can ask any university biology department, there are tons of researchers use RNAi tech on their research.Or take a look at biology literature, it shows how bright the RNAi future is.

The reason I recommend RNAI is this week biotech analysts raise RNAI's target to $8-$10 and wrote a very positive report on RNAI's product. Sirna expects to initiate IND-enabling toxicology studies in the first quarter of 2006 followed by the filing of an Investigational New Drug (IND) application with the U.S. FDA by the fourth quarter of 2006.

This is not a penny stock and is not a micro biotech company. This company's business is huge and has tremedous potential in developing new drug to cure Hepatitis, HIV, Asthma, Oncology, etc.
 
Like Peter Lynch said: "Buy what you buy.", Here is what customer say about NDN:

Bargain Hunters Head to Dollar StoresDollar Stores Attract All Income Levels
Dollar stores are a penny pincher's paradise. (ABC NEWS)

Dec. 27, 2005 — Dollar stores are growing in popularity, attracting more than the standard penny-pinching crowd.

Seventy-five percent of American households shop at these discounters, according to a survey by global management consulting and market research firm Retail Forward. One-third of all dollar-store shoppers have incomes of more than $50,000, according to a Retail Forward survey. And many have incomes far above that. There are even dollar stores in ritzy Beverly Hills, Calif.



Year-End Tax Tips
Hollywood Stars Still Dancing at 86
Kenya's Hippo, Tortoise Mark Year Together
The deep-discount, corner-store concept was born in 1955 when Dollar General store opened. Dollar General is considered the first dollar store.


"I shop here for financial reasons," said Gwendolyn Johnson, who checks supermarket prices before buying at her local dollar store. "It saves me a lot of money, and I have more food in my house for my kids to eat."

ABC News compared eight brand-name items at a Los Angeles 99 Cents Only store with identical ones sold at a supermarket chain. The bill at 99 Cents Only came to $7.92, but the same products at the grocery store totalled $14.78.

Alissa Alhman, a buyer for 99 Cents Only, said that her chain could offer the lower prices because it purchased the products on a closeout, meaning the distributor sells the item on deep discount to reduce inventory.

Avocados to aspirin, batteries to bagels, and computer cables to clothing, the merchandise moves fast — which translates to big business for the dollar stores. They have among the largest profit margins in the industry.

"They do billions of dollars every year, and each one of these companies has found neighborhoods where they do well," said Dan Butler, vice president of retail operations for the National Retail Federation. "And they know their customers and they know where they are going to find their customers."

From coast to coast, the biggest chains have grown to nearly 17,000 with $17 billion in combined revenues.

"We have two types of customers," said Eric Schiffer, chief executive officer of 99 Cents Only stores. "We have lower-income, blue-collar customers who rely on this store. But the other group of customers are more mid to upscale folks who really just enjoy getting a great deal. They have a lot of fun in the store."
 
RNAi technology is discussed all over the place, including magazine, web, academic field,since it's the next hope for cure HIV, Hepatitis B, C, Huntington's disease. Institutions holding almost 50% of RNAI's share which is unsusal for a small biotech firm, I believe those biotech analysts are very optimistic on Sirna's techology and potential new drugs. I study the wall street webcasting on RNAI which demenstrate their strong results of Phase I and how powerful the new tech on those disease. Here is the link: http://wsw.com/webcast/rrshq7/rnai/

Do you own study on RNAi on google and you will find that people have strong interest in this new technology:

http://www.allbusiness.com/periodicals/topic/2637969-1-2.html

Something is brewing, maybe the good results of their clinical study or strong expectation of their Phase II. It is not usual that analysts strong recommend a small biotech company like that, there must be something going on. In RNAI last week after analysts boost their optimistism on it. RNAi is low float stocks which high institutions interest in it, will easily fly when the news come.
 
Forbes Ranks MPS Group and EMC Among America's Best Big Companies. These two stocks are in my high growth portfolio. Both of them have good FA and TA. Especially MPS is in the IT outsource hot sector.

Also FLEX is the best EMS company ranked by BOA analysts."Banc of America's top sector pick is Flextronics, rated at "buy" with a $12.50 target price."

I am holding tight the CHB and FLE for strong demand on the factory-built home and RV and contracts from government. Both of these two stocks are raised target by Valueline recently.

Janaury Rally effect is coming.
 
Pay attention to factory-built homes industry, booming. Take a look at the following article. Add more shares CHB and FLE here, good companies in hot sector. Government will offer contracts to either one of these two companies for rebuilding the Katrina victm states.


http://www.boston.com/yourlife/home/articles/2005/12/22/hottest_trend_in_housing/

Hottest trend in housing
December 22, 2005

Manufactured housing is the fastest growing type of housing in the country, according to the 2000 Census. The nearly 8.8 million factory-built homes, up from 315,000 in 1950, made up 7.6 percent of the country's housing stock; in a dozen counties in the South and West, mobile homes made up more than half.
 
My TA model alert on CHB base on its 3m chart and 100day MA. Will see rebounce from here. CHB has solid financial background with Forward P/E 13 and 27.17% ROE as well as low float share and over 100% institution holding. Now both its TA and FA is ranked top tier in my portfolio. Recent downtrend may due to homebuilding industry and real estate buble burst rumor. However, CHB's demand side is huge both from individual and government. I add FLE, which is in the same sector into my portfolio in order to increase the weight in the factory-built home sector. Will see CHB back to $15 soon.
 
Call MPS again with The service sector's growth in December marked the 33rd straight month of its expansion.
MPS specialize in IT outsoursing business and other enterprise sevices. ACN will announce earning this afternoon which should be good and will give confidence to MPS. MPS is better than ACN in sense of TA and it is mucher cheaper. My target will be at least $16
 
You must log in or register to reply here.
Back
Top